Hansoh Pharma (翰森制药) IPO: Takeaways from Recent 4+7 City Centralized Tender Results
Hansoh Pharma, a leading generic pharmaceutical manufacturer, filed an application to list on the Hong Kong Stock Exchange. In our previous...
942 Views
EM Health Care: Late Cycle Rotation
Emerging Market Health Care allocations sit towards the lower end of their 7-year range. Current levels are off their 2015 highs by a margin, with...
439 Views
Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)
Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...
640 Views
Quiddity Weekly H/A: Share Spreads & Southbound Flows [Week to 19 Oct 2018]
This insight is an H/A Spread Monitor Project offering a brief look at recent changes in H-Share/A-Share spreads, Southbound flow and impact, and...
540 Views
Initiating Coverage of CSPC (1093 HK) With Narrow Moat Rating, FVE of HKD 21.0 Per Share
We initiate coverage on CSPC Pharmaceutical (1093 HK), or CSPC, with a narrow moat rating and a fair value estimate of HKD 21.0 per share, implying...
409 Views